FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC.
DNA mutational analysis
clinical decision-making
epidermal growth factor receptor
non-small cell lung cancer
turnaround time
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
07
2022
accepted:
11
01
2023
entrez:
17
2
2023
pubmed:
18
2
2023
medline:
22
2
2023
Statut:
epublish
Résumé
Accurate testing for epidermal growth factor receptor (
Identifiants
pubmed: 36798672
doi: 10.3389/pore.2023.1610707
pii: 1610707
pmc: PMC9927408
doi:
Substances chimiques
ErbB Receptors
EC 2.7.10.1
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1610707Informations de copyright
Copyright © 2023 Behnke, Cayre, De Maglio, Giannini, Habran, Tarsitano, Chetta, Cappellen, Lespagnol, Le Naoures, Massazza, Destro, Bonzheim, Rau, Battmann, Kah, Watkin and Hummel.
Déclaration de conflit d'intérêts
IB declares receipt of honoraria from Novartis, Bayer, Pfizer, Takeda, AstraZeneca and BMS. EW declares the receipt of honoraria from AstraZeneca and MSD. MH declares membership in advisory councils or committees for AstraZeneca, Roche, Novartis, Pierre Fabre GDM, Sanofi, MSD and BMS; and receipt of grants or funds from AstraZeneca. Author EW was employed by the company CYPATH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from AstraZeneca, Cambridge, UK and Biocartis, Mechelen, Belgium. Biocartis were involved in study design, and analysis and interpretation of data. AstraZeneca were not involved in study design or analysis and interpretation of data. The funders were not involved in collection of data. The funders reviewed the manuscript before submission.
Références
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
JAMA Netw Open. 2021 Mar 1;4(3):e211793
pubmed: 33755165
J Mol Diagn. 2019 Nov;21(6):1010-1024
pubmed: 31445213
Leukemia. 2011 Apr;25(4):671-80
pubmed: 21252984
JCO Precis Oncol. 2020 Sep 21;4:
pubmed: 33015530
Ann Oncol. 2015 Dec;26(12):2477-82
pubmed: 26420428
Curr Oncol. 2020 Dec;27(6):321-329
pubmed: 33380864
J Clin Oncol. 2014 Nov 10;32(32):3673-9
pubmed: 25311215
Am Soc Clin Oncol Educ Book. 2018 May 23;38:708-715
pubmed: 30231309
Curr Oncol. 2021 Nov 03;28(6):4432-4445
pubmed: 34898548
J Pathol Transl Med. 2021 May;55(3):181-191
pubmed: 33966368
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Clin Cancer Res. 2015 Sep 1;21(17):3924-33
pubmed: 25964297
J Thorac Oncol. 2012 Jun;7(6):1049-52
pubmed: 22588155
J Thorac Oncol. 2008 Aug;3(8):832-9
pubmed: 18670300
J Thorac Oncol. 2009 Jul;4(7):809-15
pubmed: 19487967
Cancer Discov. 2014 Sep;4(9):1046-61
pubmed: 24893891
Respirology. 2020 Sep;25(9):933-943
pubmed: 32335992
Cytopathology. 2015 Oct;26(5):312-7
pubmed: 25376259
J Clin Pathol. 2018 Aug;71(8):745-750
pubmed: 29798838
J Clin Oncol. 2018 Aug 28;:JCO2018783118
pubmed: 30153097
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
BMC Cancer. 2020 Apr 3;20(1):275
pubmed: 32245434
Ann Oncol. 2020 Nov;31(11):1491-1505
pubmed: 32853681
Ann Oncol. 2015 Jul;26(7):1415-21
pubmed: 25922063
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
JTO Clin Res Rep. 2020 Sep;1(3):
pubmed: 33511359
Transl Lung Cancer Res. 2015 Oct;4(5):584-97
pubmed: 26629427
J Clin Pathol. 2022 Apr;75(4):241-249
pubmed: 33514586
Ann Oncol. 2015 Sep;26(9):1883-1889
pubmed: 26105600
Ann Oncol. 2021 Dec;32(12):1637-1642
pubmed: 34481037
J Mol Diagn. 2021 Mar;23(3):310-322
pubmed: 33346146
Arch Pathol Lab Med. 2018 Mar;142(3):321-346
pubmed: 29355391
J Clin Oncol. 2021 Mar 20;39(9):1040-1091
pubmed: 33591844
Transl Lung Cancer Res. 2019 Jun;8(3):286-301
pubmed: 31367542
Sci Rep. 2021 May 18;11(1):10470
pubmed: 34006948
J Clin Oncol. 2018 Sep 10;36(26):2702-2709
pubmed: 30059262
Lung Cancer. 2021 Apr;154:161-175
pubmed: 33690091
Science. 2004 Jun 4;304(5676):1497-500
pubmed: 15118125
Nat Protoc. 2017 Feb;12(2):213-218
pubmed: 28055035
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
Cancers (Basel). 2020 Apr 13;12(4):
pubmed: 32294880
Genes (Basel). 2022 Apr 29;13(5):
pubmed: 35627184
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Oncotarget. 2016 Nov 29;7(48):78985-78993
pubmed: 27738317
Cancer Treat Commun. 2016;9:41-43
pubmed: 28111612
N Engl J Med. 2020 Oct 29;383(18):1711-1723
pubmed: 32955177
Br J Cancer. 2019 Oct;121(9):725-737
pubmed: 31564718
Clin Lung Cancer. 2017 Nov;18(6):651-659
pubmed: 28479369
Semin Cancer Biol. 2020 Apr;61:167-179
pubmed: 31562956
Nat Rev Clin Oncol. 2022 Jan;19(1):51-69
pubmed: 34561632
J Clin Pathol. 2020 Jul 31;:
pubmed: 32737190
Oncotarget. 2017 Oct 4;8(61):103055-103062
pubmed: 29262544